RT Journal Article
SR Electronic
T1 Effects and Mechanisms of Anti-CD44 Monoclonal Antibody A3D8 on Proliferation and Apoptosis of Sphere-Forming Cells With Stemness From Human Ovarian Cancer
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 1367
OP 1375
DO 10.1097/IGC.0b013e3182a1d023
VO 23
IS 8
A1 Yong-Rui Du
A1 Ying Chen
A1 Yan Gao
A1 Xiu-Long Niu
A1 Ya-Jing Li
A1 Wei-Min Deng
YR 2013
UL http://ijgc.bmj.com/content/23/8/1367.abstract
AB Objective CD44+ human ovarian cancer stem cells (CSCs) and CSC-like cells have been identified and characterized. Compelling evidence has revealed that CD44 is involved in the occurrence and development of cancers. Our previous study showed that sphere-forming cells (SFCs) from the human ovarian cancer cell line SKOV-3 had CSC capacity. Therefore, in the present study, we aimed to investigate the effects and mechanisms of the anti-CD44 monoclonal antibody A3D8 on the proliferation and apoptosis of SFCs to explore novel strategies for the treatment of ovarian cancer.Methods We investigated the effects and mechanisms of A3D8 on the proliferation and apoptosis of SFCs using the MTS assay, cell cycle analysis, an annexin V-fluorescein isothiocyanate/propidium iodide kit, Rh123 apoptosis detection kit, real-time reverse transcription polymerase chain reaction and Western blotting.Results After CD44 ligation by A3D8, SFC cell proliferation was notably attenuated, cell cycle progression was arrested in the S phase, and apoptosis was significantly increased. The effect of A3D8 was enhanced in a dose- and time-dependent manner, and the effect of apoptosis induction by DDP was enhanced by combination treatment with A3D8. Furthermore, the messenger RNA expression levels of p21 and caspase-3 were up-regulated, whereas those of CDK2, cyclinA, and Bcl-2 were down-regulated. The protein expression levels of caspase-3 were up-regulated, whereas those of CDK2, cyclinA, and Bcl-2 were down-regulated.Conclusions Our findings indicate that anti-CD44 monoclonal antibodies may be a potential strategy for the treatment of human ovarian cancer after conventional therapy via inhibition of growth and the promotion of apoptosis in SFCs with stemness.